Abstract | BACKGROUND/AIMS: METHODS: From March 2001 to November 2004, 49 patients with advanced HCC with PVTT (size>8 cm, modified UICC stage IVa) were enrolled in this retrospective study. Twenty two patients underwent more than 2 cycles of TACL ( adriamycin 50 mg/m(2), cisplatin 60 mg/m(2), 5-fluorouracil 200 mg/m(2) every 4-6 weeks) without 3D-CRT, while 27 patients underwent consecutive TACL with 3D-CRT (40-45 Gy for 4-5 weeks) that was started one week after the 1st TACL. The response was assessed by a computed tomography (CT) and the serum alpha-fetoprotein (AFP) level at 1-2 month intervals. RESULTS: The objective response rates in the TACL group and TACL with 3D-CRT group were 18% and 48% at 3 months (P=0.051), and 10.5% and 42% at 6 months (P=0.024) respectively. The median survival time was 13 months and 13.5 months in TACL and TACL with 3D-CRT groups, respectively (P=0.502). The treatment response was better in the TACL with 3D-CRT group but there was no significant difference in survival between the two groups. Most toxicities in the two groups were mild, not exceeding grade 1 according to the WHO criteria. CONCLUSIONS: For patients with a huge HCC with PVTT, TACL with 3D-CRT achieved some meaningful clinical benefit. Prospective controlled trials will be needed to confirm the real benefit of TACL combined with 3D-CRT.
|
Authors | Chan Ran You, Jeong Won Jang, Seok Hui Kang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Ihl Bhong Choi, Dong Hoon Lee, Ho Jong Chun, Byung Gil Choi |
Journal | The Korean journal of hepatology
(Korean J Hepatol)
Vol. 13
Issue 3
Pg. 378-86
(Sep 2007)
ISSN: 1738-222X [Print] Korea (South) |
PMID | 17898554
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Hepatocellular
(complications, radiotherapy, therapy)
- Chemoembolization, Therapeutic
(methods)
- Combined Modality Therapy
- Data Interpretation, Statistical
- Female
- Humans
- Liver Neoplasms
(complications, radiotherapy, therapy)
- Male
- Middle Aged
- Portal Vein
- Radiotherapy, Conformal
(adverse effects, methods)
- Severity of Illness Index
- Survival Analysis
- Venous Thrombosis
(etiology, radiotherapy, therapy)
|